Brief report: the prevalence of smoking and vaping among adolescents with/without intellectual disability in the UK.
Abstract
BACKGROUND
Few studies have investigated the prevalence of smoking among young people with/without intellectual disability. To date, no study has investigated the prevalence of vaping among young people with/without intellectual disability.
METHODS
Secondary analysis of data collected on 11 726 adolescents at age 14 years (2015) and from 9528 adolescents at age 17 years (2018) in the UK's Millennium Cohort Study.
RESULTS
The prevalence of smoking at ages 14 and 17 and of vaping at age 14 was similar among adolescents with and without intellectual disability. There was some evidence to suggest that at age 17, the prevalence of more frequent vaping was higher among girls with intellectual disability than among their female peers (5.2% vs. 1.6%, P < 0.05).
CONCLUSIONS
Further large-scale population-based research is required to determine the prevalence of smoking and vaping among people with intellectual disability. Evidence that at age 17, the prevalence of vaping was higher among girls with potential intellectual disability than among their female peers also warrants further investigation given the increasing evidence on the potential harm to health and well-being associated with vaping.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 9,528 participants or records.
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.